30Aug
21Aug
Second Wave of COVID-19 Vaccines Could Resolve Vaccine Inequity
There’s one significant ray of hope for those frustrated by vaccine inequity: second-generation coronavirus vaccines are currently showing promise in clinical trials, many of which may prove highly effective as well as cheaper and easier to distribute around the world. The AKS-452 candidate produced by Massachusetts-based Akston Biosciences, for example, recently entered Phase II trials at the University Medical Center Groningen (UMCG), one of the largest hospitals in the Netherlands. Read more >>
20Aug
From Defense To Offense: Pixability’s Duffy Flips CTV Suitability On Its Head
Matt Duffy of Pixability, a vendor of brand safety tooling for YouTube and other platforms, describes how the category is evolving. Duffy points to a study from Global Alliance for Responsible Media and data from Comscore showing how comfortable advertisers have become with those channels. “It showed (that) YouTube is now over 99% brand-safe for advertisers,” he says. “According to Comscore, over 40% of CTV watch time is YouTube.” And Pixability just commissioned its own survey of ad buyer attitudes...
18Aug
9 Rhode Island companies make this year’s Inc. 5000 list
Nine Rhode Island-based companies have made this year's Inc. 5000 list, the financial magazine's annual ranking of the fastest-growing privately held companies in the country. Topping the 2021 list among Ocean State companies was Luna Pharmaceuticals, which clocked in at No. 1,852 overall with 245% revenue growth. In fact, Luna Pharmaceuticals is the official name of the company behind Premama Wellness, a Providence-based startup that sells supplements for maternity wellness. Premama last May attracted its first institutional investor since launching...
18Aug
ZetrOZ Systems is Helping Americans Get Back to Work
As America gets back to work, businesses are placing a higher premium on the health and wellbeing of their employees. ZetrOZ Systems, developers of the Sustained Acoustic Medicine (sam®) wearable pain relief ultrasound device, is helping employers minimize the impact and likelihood of workplace injuries. Read more >>
17Aug
40 Under Forty 2021: David Zamarin
Not many people can boast they started their career by launching a company in the 10th grade, but David Zamarin can. He founded DetraPel to solve a problem, at the time, thought impossible in the chemical industry. Less than 10 years later, as the leader of an 18-employee company which has developed PFAS-free liquid repellents and protectors for porous and non-porous surfaces, Zamarin has been featured everywhere from ABC’s Shark Tank to the Forbes 30 Under 30 list. Zamarin is...
17Aug
Wasabi Technologies Earns High Scores on CRN’s 2021 Annual Report Card
Wasabi Technologies, the hot cloud storage company, today announced that CRN®, a brand of The Channel Company, is recognizing it as a winner in the Cloud Storage category of the 2021 CRN Annual Report Card (ARC) Awards. This award celebrates the company’s success and efforts in earning high solution provider satisfaction with the products and services it provides to its channel partners. Read more >>
14Aug
A Second-Generation of Cloud-Based Video Surveillance Services
The popularity of cloud-based video surveillance services proves the value propositions of these services. Over the past years, however, the industry has experienced painful drawbacks from using this first generation of services. The most concerning drawback is cybersecurity and the potential for compromised video. To provide cloud cybersecurity, we need to start from the user of the services. To protect against ransomware, the cloud storage systems must have adequate “redundancy and immutability,” these features are already available from some cloud...
13Aug
mRNA deals will not solve Africa’s vaccine shortfall, but the second generation of vaccines may
...One especially promising option for overcoming sub-Saharan Africa’s logistical constraints is currently being trialled by Massachusetts-based firm Akston Biosciences, whose shelf-stable vaccine candidate entered Phase I/II trials in the Netherlands earlier this year. Akston’s AKS-452 vaccine has already shown positive results in initial analyses, producing a robust antibody response to strains of Covid such as the alpha and gamma variants. Read more >>
13Aug